Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage

We conducted a trial of prophylactic platelet transfusions to evaluate the effect of platelet dose on bleeding in patients with hypoproliferative thrombocytopenia

Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery

Some observational studies have reported that transfusion of red-cell units that have been stored for more than 2 to 3 weeks is associated with serious, even fatal, adverse events. Patients undergoingcardiac surgery may be especially vulnerable to the adverse effects of transfusion

Recent advances in transfusions in neonates/infants [version 1; referees: 2 approved]

Transfusions of red blood cells (RBCs), platelets, and plasma are critical therapies for infants and neonates (particularly preterm neonates) in the neonatal intensive care unit, who are the most frequently transfused subpopulation across all ages. Although traditionally a significant gap has existed between the blood utilization and the evidence base essential to adequately guide transfusion practices in infants and neonates, pediatric transfusion medicine is evolving from infancy and gradually coming of age. It is entering an exciting era with recognition as an independent discipline, a new and evolving high-quality evidence base for transfusion practices, novel technologies and therapeutics, and national/international collaborative research, educational, and clinical efforts. Triggers and thresholds for red cell transfusion are accumulating evidence with current phase III clinical trials. Ongoing trials and studies of platelet and plasma transfusions in neonates are anticipated to provide high-quality evidence in years to come. This article aims to summarize the most current evidence-based practices regarding blood component therapy in neonates. Data on the use of specific components (RBCs, plasma, and platelets) are provided. We attempt to define thresholds for anemia, thrombocytopenia, and abnormal coagulation profile in neonates to highlight the difficulties in having a specific cutoff value in neonates and preterm infants. Indications for transfusion of specific products, transfusion thresholds, and current practices and guidelines are provided, and possible adverse outcomes and complications are discussed. Finally, the critical research knowledge gaps in these practices as well as ongoing and future research areas are discussed. In an era of personalized medicine, neonatal transfusion decisions guided by a strong evidence base must be the overarching goal, and this underlies all of the strategic initiatives in pediatric and neonatal transfusion research highlighted in this article

Epidemiological Profiles of Foreign-Born and US-Born Hispanic Blood Donors in a Major Metropolitan Area in the United States

Background. The explosive growth of Hispanics in the US makes this population a significant and untapped source for blood donation. Methods. A cross-sectional study was performed to evaluate blood donation behaviors and demographics of foreign-born and US-born Hispanic donors between 2006 and 2009 in metropolitan Atlanta, GA, USA. Bivariate analyses and multivariate logistic regression were used to assess factors associated with foreign-born donors. Results. 5,119 foreign-born and 11,841 US-born Hispanics donated blood. Foreign-born Hispanic donors were more likely than US-born donors to be blood group O (57.6% versus 52.0%; P<.001) and more frequent donors (2.2 versus 2.0; P<.001). Cuban-born donors had the highest rates of return donation (63.2%). In contrast, Mexicans, the most prevalent subpopulation among foreign-born Hispanic donors (31.8%), had the lowest rates of return donation (42.0%). Conclusions. The heterogeneity found among Hispanic donors in this study is valuable for the design of recruitment strategies to increase blood donations